Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

Introduction to RejuvenAir^®

9 million Americans struggle with the debilitating symptoms of COPD with Chronic Bronchitis.¹ The RejuvenAir System offers a unique solution that is aimed at treating the underlying cause of the disease; something no drug or device on the market does today.

The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.

^{1. American Lung Association.}

CAUTION: Investigational device. Limited by Federal law to investigational use.

About COPD with Chronic Bronchitis

Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).

Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.

The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life. While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.

Learn about our Clinical Trial

How Metered Cryospray Works

In Chronic Bronchitis patients, the airways have been damaged. Cilia, the tiny hair-like cells lining the lungs that help move mucus and debris out of the airway, become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

How Metered Cryospray Works

-196° C flash freeze causes instant cell death

Preservation of extracellular matrix (ECM)

Intact ECM enables healing with limited scarring and fibrosis

In Chronic Bronchitis patients, the airways have been damaged. Cilia, tiny hair-like cells lining the lungs that help move mucus and debris out of the airway become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

RejuvenAir rejuvenates the airways.

The SPRAY-CB Clinical Trial

Researching a NEW option for people living with Chronic Bronchitis

The RejuvenAir System Trial for COPD with Chronic Bronchitis (SPRAY-CB) is currently recruiting patients in the United States. This trial is designed to continue to explore the safety and effectiveness of metered cryospray treatments in patients suffering from Chronic Bronchitis.

Find out more about the SPRAY-CB Trial

To find out if you or somebody you know might qualify, watch the video then answer the short questionnaire below and register to continue the process.

Watch the video

Find out if you qualify:

Where the study is enrolling

The map below shows the study centers that are enrolling. For more information, refer to the ClinicalTrials.gov website.

Details are available for the United States SPRAY-CB Study and a smaller European Study.

The RejuvenAir System is CE marked in the European Union and limited to investigational use in the United States and is currently not for sale.

Title	Address	Description
Temple University, Philadelphia	1801 N Broad St, Philadelphia, PA 19122, USA	ENROLLING Principal Investigator: Dr. G.J. Criner, Interventional Pulmonology /Pulmonary Care.
UC Davis Medical Center, Sacramento	2279 45th St, Sacramento, CA 95817, USA	ENROLLING Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology /Pulmonary Care
UT Southwestern Medical Center, Dallas	5939 Harry Hines Blvd, Dallas, TX 75390, USA	ENROLLING Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology /Pulmonary Care
El Camino Hospital, Mountain View	701 E El Camino Real, Mountain View, CA 94040, USA	ENROLLING Principal Investigator: Dr. Ganesh Krishna, Interventional Pulmonology /Pulmonary Care
Beth Israel Deaconess Medical Center, Boston	185 Pilgrim Rd, Boston, MA 02215, USA	ENROLLING Principal Investigator: Dr. Adnan Majid, Interventional Pulmonology /Pulmonary Care
Sarasota Memorial Hospital, Sarasota	1700 S Tamiami Trail, Sarasota, FL 34239, USA	ENROLLING Principal Investigator: Dr. Joseph Seaman, Interventional Pulmonology /Pulmonary Care
Medical University of South Carolina, Charleston	96 Jonathan Lucas St, Charleston, SC 29425, USA	ENROLLING Principal Investigator: Dr. Charlie Strange, Interventional Pulmonology /Pulmonary Care
Duke University School of Medicine, Durham	Durham, NC, USA	ENROLLING Principal Investigator: Dr. Wahidi, Interventional Pulmonology /Pulmonary Care
Advanced Pulmonary Research Institute, Loxahatchee	13005 Southern Blvd, Loxahatchee, FL 33470, USA	ENROLLING Principal Investigator: Dr. Warshoff, Interventional Pulmonology /Pulmonary Care
Cooper Health	New Brunswick, NJ, USA	ENROLLING Principal Investigator: Dr. Wissam Abouzgheib, Bronchoscopy & Interventional Pulmonology
The Cleveland Clinic Foundation, Cleveland	9500 Euclid Ave, Cleveland, OH 44106, USA	ENROLLING Principal Investigator: Dr. Gildea, Interventional Pulmonology /Pulmonary Care.
University Of Wisconsin Hospital, Madison	Highland Ave, Madison, WI, USA	ENROLLING Principal Investigator: Dr. Ferguson, Interventional Pulmonology /Pulmonary Care
Louisiana State University Medical Center, Shreveport	Shreveport, LA 71103, USA	ENROLLING Principal Investigator: Dr. Robert Holladay, Bronchoscopy & Interventional Pulmonology
University of Cincinnati, Cincinnati	Lindner Hall, 2925 Campus Green Dr, Cincinnati, OH 45221, USA	ENROLLING Principal Investigator: Dr. Alejandro Adolfo Aragaki, Bronchoscopy & Interventional Pulmonology
St. David's Medical Center, Austin	1015 E 32nd St, Austin, TX 78705, USA	ENROLLING Principal Investigator: Dr. D. Dekeratry, Interventional Pulmonology
University of Maryland, Baltimore	Um Professional Bldg, 419 W Redwood St, Baltimore, MD 21201, USA	ENROLLING Principal Investigator: Dr. Ashutosh Sachdeva, Interventional Pulmonology /Pulmonary Care.
Clinical Research Associates of Central PA	100 Hospital Ave, DuBois, PA 15801, USA	ENROLLING Principal Investigator: Dr. Sandeep Bansal, Bronchoscopy & Interventional Pulmonology
Dartmouth-Hitchcock Medical Center, Lebanon	1 Medical Center Dr, Lebanon, NH 03766, USA	ENROLLING Principal Investigator: Dr. David Feller-Hopman, Interventional Pulmonology /Pulmonary Care.
Prisma Health-Midlands, Columbia	Columbia, SC, USA	ENROLLING Principal Investigator: Dr. W Tillis, Interventional Pulmonology /Pulmonary Care.
Ohio State University, Columbus	Davis Heart and Lung Research Institute, 473 W 12th Ave, Columbus, OH 43210, USA	ENROLLING Principal Investigator: Dr. Christian Ghattas, Interventional Pulmonology /Pulmonary Care
Spectrum Health, Grand Rapids	4100 Lake Dr SE, Grand Rapids, MI 49546, USA	ENROLLING Principal Investigator: Dr. Cumbo-Nacelli, Interventional Pulmonology /Pulmonary Care
HonorHealth, Scottsdale	Scottsdale, AZ, USA	NOW ENROLLING Principal Investigator: Dr. Richard Sue, Interventional Pulmonology /Pulmonary Care
Northwestern University	Rebecca Crown Center, 633 Clark St, Evanston, IL 60208, USA	NOT YET ENROLLING
Medical College of Wisconsin	8701 W Watertown Plank Rd, Wauwatosa, WI 53226, USA	NOT YET ENROLLING

About Us

CSA Medical is committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. We are advancing our core liquid nitrogen spray technology to target the underlying cause of Chronic Bronchitis – the over production of mucus and damaged cilia within the airways. By targeting and destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung.

CSA Medical is currently conducting clinical studies with the RejuvenAir System. The clinical study aims to evaluate the effectiveness of the RejuvenAir System to reduce mucous production, cough, and inflammation in the Chronic Bronchitis patient population and to determine the extent of improvement in their overall health and quality of life.

News & Resources

First Randomized Controlled Study with RejuvenAir® for Chronic Bronchitis shows Clinically Significant Results

Sep 6, 2022

Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ -- CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir®...

CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

May 13, 2021

These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...

CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis

Apr 19, 2021

Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...

More news & resources…

131 Hartwell Avenue
Lexington
Massachusetts 02421

Phone: 781.538.4720
Toll Free: 866.481.7786
Fax: 866.300.5183
Email: info@rejuvenair.com

CAUTION: Investigational device. Limited by Federal law to investigational use.

Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis